The publisher regrets that the authorship list was incorrectly published, the corrected list is above.
The publisher would like to apologise for any inconvenience caused.
. 2022 Jul 13;7(4):100549. doi: 10.1016/j.esmoop.2022.100549
Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’
[ESMO Open Volume 7, Issue 2, April 2022, 100447]
S Ochsenreither
1,2,3,∗, WM Fiedler
4, G Del Conte
5, M Macchini
5, I Matos
6, B Habel
7, I Ahrens-Fath
7, F Raspagliesi
8, D Lorusso
8, U Keilholz
1,3,9, C Rolling
4, M Kebenko
4, KF Klinghammer
1,2, O Saavedra
6, H Baumeister
7, A Zurlo
7, A Garralda
6
S Ochsenreither
1Charité Comprehensive Cancer Center, Berlin
2Charité, Department of Hematology, Oncology and Tumor Immunology, Berlin
3German Cancer Consortium (DKTK), Berlin
Find articles by S Ochsenreither
WM Fiedler
4University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany
Find articles by WM Fiedler
I Matos
6Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain
Find articles by I Matos
F Raspagliesi
8Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Find articles by F Raspagliesi
U Keilholz
1Charité Comprehensive Cancer Center, Berlin
3German Cancer Consortium (DKTK), Berlin
9Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
Find articles by U Keilholz
C Rolling
4University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany
Find articles by C Rolling
M Kebenko
4University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany
Find articles by M Kebenko
KF Klinghammer
1Charité Comprehensive Cancer Center, Berlin
2Charité, Department of Hematology, Oncology and Tumor Immunology, Berlin
Find articles by KF Klinghammer
O Saavedra
6Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain
Find articles by O Saavedra
A Garralda
6Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain
Find articles by A Garralda
1Charité Comprehensive Cancer Center, Berlin
2Charité, Department of Hematology, Oncology and Tumor Immunology, Berlin
3German Cancer Consortium (DKTK), Berlin
4University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany
5Fondazione IRCCS San Raffaele Hospital, Milan, Italy
6Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain
7Glycotope GmbH, Berlin, Germany
8Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
9Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
∗
Correspondence to: S. Ochsenreither sebastian.ochsenreither@charite.de
Collection date 2022 Aug.
© 2022 The Author(s)
PMCID: PMC9293584 PMID: 35841804